Agios Pharmaceuticals, Inc. (AGIO) fair value analysis
Nasdaq · Updated 2026-10-19
AGIO price how computed
Valuation status
No fair-value estimate yetAGIO has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for AGIO yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $31.32
- Sector
- Healthcare
- 12-month range
- $22.34–$45.49
- Market cap
- $1.87B
- From 52-week high
- -31.1%
- Shares outstanding
- 59.7M
- Rank in Healthcare by quality score
- #93 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines for rare genetic diseases and other serious conditions. The company operates globally with a focus on research, development, and commercialization of its therapeutic products.
AGIO currently ranks #93 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.87B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $98.3M
- Net margin
- -418.2%
- EPS (TTM)
- $-7.01
- Gross margin
- 93.3%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- 168.2%
- Shares outstanding
- 59.7M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 42 · neutral
- 50-day average
- $33.06
- 200-day average
- $31.27
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+9.1%)
2026-03 ▲ beat (+5.6%)
2025-12 ▲ beat (+5.1%)
2025-09 ▲ beat (+6.3%)
2025-06 ▼ miss (-10.3%)
2025-03 ▲ beat (+11.9%)
2024-12 ▼ miss (-6.7%)
2024-09 ▼ miss (-118.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 3 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $46
- Target vs last price
- +46.9%
What our data shows for AGIO
- Shares are trading in the middle of their 12-month price range of $22.34–$45.49.
- The 14-day relative strength index sits at a neutral 42.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- AGIO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the AGIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is AGIO stock undervalued?
TickrTrends has no fair-value estimate for AGIO yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is AGIO's TickrTrends verdict?
AGIO is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does AGIO compare to other Healthcare stocks?
AGIO ranks #93 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is AGIO overbought or oversold?
AGIO's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does AGIO report earnings next?
AGIO's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does AGIO usually beat earnings estimates?
Over its last 8 reported quarters AGIO beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AGIO?
Of 10 analysts covering AGIO, 7 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $46 (+46.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.